Cellectar Biosciences Inc Cash Flow-to-Debt Ratio
Cellectar Biosciences Inc cash flow-to-debt ratio. Cellectar Biosciences Inc (CLRB) has a Cash Flow-to-Debt Ratio of -0.86x as of December 2025, meaning its operating cash flow of $-4.34 Million could theoretically repay -1% of its total liabilities ($5.06 Million) in one year. Check Cellectar Biosciences Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cellectar Biosciences Inc (2004–2025)
Cash flow-to-debt ratio of Cellectar Biosciences Inc from 2004 to 2025. Historical debt coverage capacity for Cellectar Biosciences Inc across 22 annual periods. Check Cellectar Biosciences Inc (CLRB) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cellectar Biosciences Inc Cash Flow-to-Debt Ratio by Year (2004–2025)
Cellectar Biosciences Inc cash flow-to-debt ratio by year from 2004 to 2025. Year-by-year debt coverage analysis for Cellectar Biosciences Inc. For the full cash flow conversion analysis, see CLRB cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.57x | $-23.12 Million | $5.06 Million | ▼ -7.4% |
| 2024 | -4.26x | $-47.58 Million | $11.18 Million | ▼ -239.9% |
| 2023 | -1.25x | $-32.38 Million | $25.85 Million | ▲ +40.1% |
| 2022 | -2.09x | $-25.22 Million | $12.05 Million | ▲ +61.5% |
| 2021 | -5.43x | $-22.57 Million | $4.16 Million | ▼ -50.6% |
| 2020 | -3.60x | $-13.93 Million | $3.86 Million | ▲ +1.6% |
| 2019 | -3.66x | $-11.69 Million | $3.19 Million | ▲ +42.6% |
| 2018 | -6.38x | $-11.44 Million | $1.79 Million | ▼ -22.6% |
| 2017 | -5.21x | $-11.02 Million | $2.12 Million | ▼ -12.2% |
| 2016 | -4.64x | $-8.28 Million | $1.78 Million | ▼ -236.0% |
| 2015 | -1.38x | $-8.21 Million | $5.95 Million | ▲ +58.2% |
| 2014 | -3.31x | $-8.84 Million | $2.67 Million | ▼ -84.8% |
| 2013 | -1.79x | $-9.15 Million | $5.12 Million | ▲ +64.1% |
| 2012 | -4.99x | $-6.59 Million | $1.32 Million | ▲ +9.6% |
| 2011 | -5.52x | $-5.97 Million | $1.08 Million | ▲ +11.3% |
| 2010 | -6.22x | $-7.80 Million | $1.25 Million | ▼ -1999.9% |
| 2009 | -0.30x | $-10.62 Million | $35.83 Million | ▲ +87.9% |
| 2008 | -2.46x | $-17.33 Million | $7.05 Million | ▼ -209.9% |
| 2007 | -0.79x | $-13.47 Million | $16.98 Million | ▲ +83.9% |
| 2006 | -4.93x | $-6.47 Million | $1.31 Million | ▲ +55.4% |
| 2005 | -11.05x | $-2.40 Million | $217.16K | ▼ -12553.9% |
| 2004 | -0.09x | $-389.18K | $4.46 Million | — |